AntibioTx is committed to fighting the threat from multi-drug resistant bacteria. Our people have developed more than 20 marketed medicines generating annual revenues in excess of 5 B USD.
Bacterial infections are a leading cause of death worldwide and the relentless evolution of antimicrobial resistance renders currently available antibiotics ineffective at an increasing pace.
Platform & Pipeline
Learn about the Tx-class and the pipeline of AntibioTx. In particular, ATx201 which is our lead candidate and is being developed for topical treatment of skin infections and atopic dermatitis.